Par Pharmaceutical Reports Third-Quarter 20...(long-term debt ...),Health

Accounts payable 30,546 48,297

Payables due to distribution agreement

partners 65,586 89,585

Accrued salaries and employee benefits 13,413 15,510

Accrued expenses and other current

liabilities 25,168 18,833

Income taxes payable 58 16,974

Total current liabilities 334,790 393,668

Long-term debt, less current portion - -

Other long-term liabilities 13,718 -

Commitments and contingencies - -

Stockholders' equity:

Preferred Stock, par value $0.0001 per

share, authorized 6,000,000 shares;

none issued and outstanding - -

Common Stock, par value $0.01 per share,

authorized 90,000,000 shares, issued

36,421,650 and 35,901,276 shares 364 359

Additional paid-in-capital 267,994 254,013

Retained earnings 245,837 200,256

Accumulated other comprehensive income

(loss) 1,351 (431)

Treasury stock, at cost 942,716 and

889,245 shares (34,564) (33,188)

Total stockholders' equity 480,982 421,009

Total liabilities and stockholders' equity $829,490 $814,677

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data
'/>"/>